Weekly shot shows promise for helping kids with dwarfism grow
NCT ID NCT05929807
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a weekly injection called TransCon CNP in children and teens with achondroplasia, the most common form of dwarfism. The goal is to see if it is safe and helps improve growth over several years. Participants who completed a previous TransCon CNP trial can join this long-term extension, receiving the same dose until their bones stop growing.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
TransCon CNP (a weekly injection of C-type natriuretic peptide)
What this could lead to
If successful, this treatment could help children with achondroplasia grow taller and improve bone development, potentially reducing some complications of the condition.
What could go wrong
This is an early-to-mid stage trial with no placebo group, so results may be less reliable. Possible side effects include injection site reactions and unknown long-term risks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACHONDROPLASIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ascendis Investigational Site
Aurora, Colorado, 80045, United States
-
Ascendis Investigational Site
Wilmington, Delaware, 19803, United States
-
Ascendis Investigational Site
Saint Paul, Minnesota, 55102, United States
-
Ascendis Investigational Site
Houston, Texas, 77030, United States
-
Ascendis Investigational Site
Linz, 4020, Austria
-
Ascendis Investigational Site
Montreal, H3T 1C5, Canada
-
Ascendis Investigational Site
Berlin, 13353, Germany
-
Ascendis Investigational Site
Auckland, 1023, New Zealand
-
Ascendis Investigational Site
Coimbra, 3000-602, Portugal
-
Ascendis Investigational Site
Vitoria-Gasteiz, 1008, Spain
-
Ascendis Pharma Investigational Site
Little Rock, Arkansas, 72202, United States
-
Ascendis Pharma Investigational Site
Columbia Falls, Montana, 65212, United States
-
Ascendis Pharma Investigational Site
Buffalo, New York, 14203, United States
-
Ascendis Pharma Investigational Site
Madison, Wisconsin, 53705, United States
-
Ascendis Pharma Investigational Site
Parkville, Victoria, 3052, Australia
-
Ascendis Pharma Investigational Site
Copenhagen, 2100, Denmark
-
Ascendis Pharma Investigational Site
Dublin, D01 YC76, Ireland